Skip to Content


In the US, Alfuzosin (alfuzosin systemic) is a member of the drug class antiadrenergic agents, peripherally acting and is used to treat Benign Prostatic Hyperplasia.

US matches:

UK matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

α₁-adrenoceptor antagonist (α₁-blocker)

Treatment of symptoms of benign prostatic hyperplasia

Chemical Name

(±)-N-[3-[(4-amino-6,7-dimetoxy-2-quinazolinyl)metylamino]propyl]tetrahydro-2-furamide (WHO)

Foreign Names

Generic Names

  • Alfuzosin (OS: BAN)
  • Alfuzosina (OS: DCIT)
  • Alfuzosine (OS: DCF)
  • Alfuzosin Hydrochloride (OS: BANM, USAN, JAN)
  • SL 77499-10 (IS: Synthélabo)
  • Alfuzosin hydrochloride (PH: Ph. Eur. 8)
  • Alfuzosin Hydrochloride (PH: BP 2016, USP 38)
  • Alfuzosine (chlorhydrate d') (PH: Ph. Eur. 8)
  • Alfuzosinhydrochlorid (PH: Ph. Eur. 8)
  • Alfuzosini hydrochloridum (PH: Ph. Eur. 8)

Brand Names


BANBritish Approved Name
BANMBritish Approved Name (Modified)
DCFDénomination Commune Française
DCITDenominazione Comune Italiana
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.